吉利德科學公司
(GILD)

  • 股價
    73.55
  • 漲跌
    0.77
  • 漲幅
    1.06%
  • 成交量
    24.2萬
YahooFinanceBusiness
There are well over 5,000 stocks on the market that pay dividends. It would take you years to analyze each one of them in detail. Fortunately, you don't have to exert such an effort.
Three Fool.com contributors have identified dividend stocks that they think are no-brainers to buy right now. Here'
    YahooFinanceBusiness
    One good year leads to another. That's typically been the pattern for the Nasdaq Composite index since its creation in 1971. The positive years for the index outnumber the negative years by nearly 3 to 1.
    History is on the side of investors hoping for the Nasdaq to keep soaring in 2024. Unsurprisi
      YahooFinanceBusiness
      In this article, we will be taking a look at the 15 most expensive medical treatments/procedures in the world. If you are not interested in reading about the landscape of expensive medical treatments, head straight to the 5 Most Expensive Medical Treatments/Procedures In The World.
      In today's ever
        YahooFinanceBusiness
        Gilead Sciences, Inc.'s (NASDAQ:GILD) dividend will be increasing from last year's payment of the same period to $0.77 on 28th of March. This makes the dividend yield 4.2%, which is above the industry average.
         See our latest analysis for Gilead Sciences 
        While it is great to have a strong divide
          YahooFinanceBusiness
          In this article, we discuss the top 11 CRISPR stocks to invest in. If you want to skip our discussion of the gene editing industry, head directly to Top 5 CRISPR Stocks To Invest In. 
          Genome editing refers to a set of technologies enabling scientists to modify an organism's DNA by adding, removing
            YahooFinanceBusiness
            Total Revenue: Full year 2023 revenue decreased by 1% to $27.1 billion, with a 4% decline in Q4 2023 to $7.1 billion year-over-year.
            Earnings Per Share (EPS): Diluted EPS for Q4 2023 was $1.14, down from $1.30 in Q4 2022, while full year EPS increased to $4.50 from $3.64.
            Product Sales: Excluding
              YahooFinanceBusiness
              Shares of Gilead Sciences (NASDAQ: GILD) are down 3.7% as of 3:30 p.m. ET Wednesday after the biopharmaceuticals giant announced mixed quarterly results relative to Wall Street's expectations.
              Gilead's fourth-quarter 2023 revenue declined 3.7% year over year to $7.115 billion, translating to non-G